Home

MPM BioVentures 2018 GP LLC

CIK 1818701 · last filed 2026-08-31

MPM BioVentures 2018 GP LLC is a corporate insider who has filed 13 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing shows the insider sold $1.8M of TRDA on Aug 31, 2026. Across all open-market trades the lifetime net is −$51.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $30.4M across reported positions. The firm reports its address in Boston, MA. 30 SEC filings were submitted jointly with MPM BioVentures 2018 LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$30.40M

Companies

2

Total Filings

13

Lifetime Open-Market Net

-$51.54M

Filer Profile

Reported Address
399 BOYLSTON STREET
SUITE 1100
BOSTON, MA 02116
Phone
(617) 425-9200
State of Incorporation
DE
Related Filers
MPM BioVentures 2018 LLC — 30 joint filings, latest 2026-08-31
MPM BIOVENTURES 2018, L.P. — 28 joint filings, latest 2026-08-31
LUKE EVNIN — 4 joint filings, latest 2026-01-14
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC — 4 joint filings, latest 2026-01-14
MPM BIOVENTURES 2018 (B), L.P. — 4 joint filings, latest 2026-01-14
Todd Foley — 2 joint filings, latest 2020-09-23
ANSBERT GADICKE — 2 joint filings, latest 2020-09-23
MPM BioVentures 2014, L.P. — 2 joint filings, latest 2020-07-29
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TRDA 10%+ Owner 4,275,693 $7.11 $30.40M -$3.23M 2 2026-08-31
iTeos Therapeutics, Inc. (ITOS) Delisted 10%+ Owner 2,108,594 $10.15 $21.40M -$48.31M 11 2025-05-15

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-31 TRDA Sell (S) −260,742 -$1.85M EDGAR
2026-08-26 TRDA Sell (S) −188,142 -$1.38M EDGAR
2025-05-15 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −1,890,573 -$15.24M EDGAR
2022-01-06 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −440,055 -$18.74M EDGAR
2021-10-14 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −170,310 -$4.63M EDGAR
2021-10-12 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −155,979 -$4.25M EDGAR
2021-10-05 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −82,698 -$2.24M EDGAR
2021-09-30 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −64,518 -$1.74M EDGAR
2021-09-27 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −160,404 -$4.45M EDGAR
2021-09-16 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −136,995 -$3.79M EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.